Dr. Shun Luo is Founder and President of Jianshun Biosciences Co., Ltd. and Thousand Oaks Biopharmaceuticals Co., Ltd. Dr. Luo has more than 25 years of experience in biopharmaceutical and biotechnology industries. He started his industry career as Principal Investigator at Ares Serono Group. Later Dr. Luo worked for Beckman Coulter, JRH/SAFC Bio, Genentech, and Amgen with increasing responsibilities of scientific staff and executive management team. His career spans from discovery research, to technology and product development, to late stage process development, and to commercial operations. Dr. Luo founded GeneXP Biosciences in Boston with VC funding in the early 2000s.
Dr. Luo graduated from Virginia Tech with his Ph.D. in Microbiology and Immunology. He was trained as a postdoc at the Department of Biological Chemistry and Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School.
In 2010, Dr. Luo was awarded Science and Technology Innovation award at Amgen (for his work on Mab productivity of 11g/L at 2000 L scale). He also led a team at Jianshun Biosciences achieved an ATF-based perfusion process at 1.5 g/L/day productivity recently.
Dr. Luo is an inventor of more than 10 U.S. patents, including Gene for FcRIII Polymorphic Isoforms (4 US Patents issued, 7 Patents pending). Dr. Luo published more than 20 papers in peer reviewed journals and publications. He is often invited speakers at national and international professional venues.